This is a routine board appointment with no immediate trading implications. Monitor for any future strategic shifts in R&D direction that Dr. Reed's presence might influence, but no catalyst is present here.
MDGL drugs
MDGL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 12 $536.20entry
- T+1 · 3mo ago −5.38%α −6.07% · $507.37
- T+5 · 3mo ago +0.74%α +1.18% · $540.16
- T+20 · 2mo ago −0.57%α +1.32% · $533.12
- T+60 · 12d ago −25.38%α −20.27% · $400.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Madrigal Pharmaceuticals appointed John C. Reed, M.D., Ph.D., a top R&D executive from Johnson & Johnson, to its Board of Directors, expanding the board from eight to nine members. This is a routine governance move that adds significant scientific and industry expertise but provides no new financial data or strategic catalysts for the stock.
Key Facts
- Board expanded from 8 to 9 members with the appointment of John C. Reed, M.D., Ph.D.
- Dr. Reed is Executive Vice President, Innovative Medicine, R&D at Johnson & Johnson and a member of its Executive Committee.
- Dr. Reed will receive an annual cash retainer of $50,000, a $10,000 committee fee, and an initial equity grant valued at $675,000 (50% options, 50% RSUs).
- Dr. Reed was appointed to the Science and Technology Committee.
- No material financial data, guidance, or operational updates were provided in this filing.
Financial Impact
No financial impact from this board appointment. Director compensation is standard and immaterial relative to a $12.4B market cap.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-055962 |
| Document: pressrelease-boardappointm.htm | 0001628280-26-055962 |
| Document: 0001628280-26-055962-index-headers.html | 0001628280-26-055962 |
| Document: 0001628280-26-055962-index.html | 0001628280-26-055962 |
| Document: 0001628280-26-055962.txt | 0001628280-26-055962 |
Track record
18 reports on MDGL
3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +10.26% at T+20 after the Jul 30, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
- Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 6, 202610d ago Insider Cluster Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 5, 202611d ago Institutional Cluster Mixed 3/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
- Nov 5, 202611d ago Press Release Bullish 5/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
- Nov 3, 202613d ago 8-K Bullish 7/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $396.32 to $432.60 Now $423.96 +6.97% ▲ +9.15% +9.74% vs SPY
- Aug 12, 202613w ago 8-K Neutral 3/10 Viewing Entry $536.20 to $540.16 Now $423.96 −20.93% ▲ +0.74% +1.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers